Related Experiment Video
Updated: May 2, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer: a next-generation engineering
Meng Zhang1,2, Huimin Li1,2, Kaisen Liao1,2
1Tongde Hospital of Zhejiang Province, Hangzhou, China.
Abstract:
The clinical translation of prostate-specific membrane antigen (PSMA)-directed chimeric antigen receptor (CAR) T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC) has reached a critical impasse. Despite compelling preclinical rationale and early biological activity, durable clinical responses remain scarce, constrained by three core solid tumor challenges: a profoundly immunosuppressive/metabolically hostile tumor microenvironment (TME), pervasive antigen heterogeneity driving immune escape, and intrinsic limitations in T-cell fitness and in vivo persistence. This review synthesizes the current translational landscape (updated to February 2026), and posits a tripartite synergistic framework to systematically deconstruct these barriers: (1) advances in CAR synthetic biology; (2) active TME reprogramming via armored CAR-T cells, stromal-targeting agents, and rational combinations; (3) next-generation cellular product paradigms, with a focus on stem cell-derived immune effectors. Emerging platforms, including induced pluripotent stem cell (iPSC)-derived CAR-T, CAR-natural killer (NK) cells, and CAR-macrophages, offer unprecedented opportunities to overcome autologous product limitations via off-the-shelf availability, enhanced persistence, and intrinsic TME resistance. We further delineate a translational roadmap emphasizing biomarker-driven adaptive trials, predictive humanized preclinical models, and accessibility strategies. All core claims are graded using the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence to ensure academic rigor. This work provides a strategic blueprint to advance PSMA-CAR-T therapy toward curative-intent mCRPC treatment, with insights broadly applicable to next-generation stem cell-derived immunotherapies.
Insights
Prostate-specific membrane antigen (PSMA)-directed chimeric antigen receptor (CAR) T-cell therapy faces challenges in treating metastatic castration-resistant prostate cancer (mCRPC). New strategies focus on overcoming the tumor microenvironment and enhancing T-cell persistence for better outcomes.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Prostate-specific membrane antigen (PSMA)-directed chimeric antigen receptor (CAR) T-cell therapy shows promise for metastatic castration-resistant prostate cancer (mCRPC).
- Clinical translation is hindered by the immunosuppressive tumor microenvironment (TME), antigen heterogeneity, and limited T-cell persistence.
- Durable responses remain scarce, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the current translational landscape of PSMA-CAR T-cell therapy for mCRPC.
- To propose a synergistic framework to overcome key therapeutic barriers.
- To outline a roadmap for advancing PSMA-CAR T-cell therapy towards curative intent.
Main Methods:
- Systematic review of PSMA-CAR T-cell therapy literature (updated to February 2026).
- Analysis of challenges including TME, antigen heterogeneity, and T-cell limitations.
- Evaluation of emerging platforms like induced pluripotent stem cell (iPSC)-derived CAR-T, CAR-NK, and CAR-macrophages.
- Grading of evidence using the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence.
Main Results:
- Advances in CAR synthetic biology offer improved T-cell function.
- TME reprogramming strategies (armored CAR-T, stromal targeting, combinations) are crucial.
- Next-generation cellular products (iPSC-derived, CAR-NK, CAR-macrophages) present off-the-shelf solutions with enhanced persistence and TME resistance.
- Biomarker-driven adaptive trials and predictive preclinical models are essential for progress.
Conclusions:
- A tripartite synergistic framework is proposed to address barriers in PSMA-CAR T-cell therapy.
- Emerging stem cell-derived immune effectors hold significant potential for mCRPC treatment.
- A strategic roadmap is delineated to accelerate the clinical translation of these advanced immunotherapies.
